 Edesa Biotech Incs NASDAQ: EDSA EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as monotherapy for moderate to severe chronic Allergic Contact Dermatitis ACD. Though blinded to treatment assignment, the studys Data and Safety Monitoring Board DSMB reported an approximately 1.7-fold difference between the treatment arms for the primary efficacy endpoint, which is the mean percent change from baseline on severity index at day 29. 